Study of the Duration and Efficacy of MYDAYIS on Adult ADHD Symptoms and Executive Function In Early Evening

Brief description of study

The purpose of this study is to examine how well a drug called MYDAYIS works on symptoms of attention deficit/hyperactivity disorder (ADHD) and executive function later in the day through the early evening (early evening approx. 14-15 hours after first morning dosing). The Food and Drug Administration (FDA) currently approved MYDAYIS for the treatment of ADHD in adults and in children over the age of 13. ADHD is a problem with sustaining attention, organization, planning, procrastination, daydreaming, restlessness, impulsivity and hyperactivity. Executive function means how you function in managing yourself and your resources to achieve a goal; like in paying attention, organizing, planning, initiating tasks and staying focused on them. It can include how you manage your emotions and keep track of what you are doing.


Clinical Study Identifier: s19-00046
ClinicalTrials.gov Identifier: NCT03945175
Principal Investigator: Lenard A Adler.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.